MDSpire - MDSpire Home
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

MDSpire News

  • August 28, 2026
FDA approves XFG-adapted COVID-19 vaccine
  • Kathryn Wighton
  • August 28, 2026
  • 2 min

Objective: To inform about the FDA approval of the XFG-adapted COVID-19 vaccine for specific populations. Approach: Approval Details: The FDA approved Pfizer an

...more

MDSpire News

  • August 28, 2026
FDA approves bictegravir and lenacapavir for HIV
  • Kathryn Wighton
  • August 28, 2026
  • 2 min
  1. The FDA approved bictegravir and lenacapavir (Bixlenvo) for adults with HIV-1 who have RNA levels below 50 copies/mL.
  2. Bixlenvo combines bictegravir 75 mg and lenacapavir 50 mg in a once-daily tablet for HIV treatment.
  3. Approval was based on phase 3 ARTISTRY-1 and ARTISTRY-2 trials showing comparable virologic suppression.
  4. Participants switching to Bixlenvo reported improved fasting lipid measures and treatment satisfaction.
  5. Common adverse reactions included headache, nausea, and diarrhea, with no new safety concerns identified.
...more

MDSpire News

  • August 28, 2026
FDA expands tirzepatide indication to cardiovascular risk reduction
  • Kathryn Wighton
  • August 28, 2026
  • 3 min
  1. The FDA approved tirzepatide to reduce major cardiovascular event risk in adults with type 2 diabetes at high risk.
  2. The approval includes reducing the risk of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke.
  3. The indication was based on the SURPASS-CVOT trial, which involved 13,299 participants with type 2 diabetes.
  4. Tirzepatide was found noninferior to dulaglutide for major adverse cardiovascular events over a median follow-up of 4 years.
  5. Common adverse events with tirzepatide included gastrointestinal issues, generally mild to moderate in severity.
...more

MDSpire News

  • August 28, 2026
FDA approves oral dermatomyositis therapy
  • Kathryn Wighton
  • August 28, 2026
  • 2 min

Objective: To announce the FDA approval of brepocitinib as the first oral treatment for dermatomyositis. Approach: Study Design: A phase 3 randomized, double-bl

...more

MDSpire News

  • August 28, 2026
AI may ease patient decision-making in rhinology
  • Andrea Surnit
  • August 28, 2026
  • 4 min
  1. Patients with chronic rhinosinusitis or nasal obstruction experienced reduced decisional conflict using ChatGPT or Google.
  2. The study involved 57 English-speaking adults randomized to use ChatGPT or Google after counseling with a rhinologist.
  3. Mean Decisional Conflict Scale scores decreased significantly in both groups, but no statistical difference was found between them.
  4. Neither intervention improved treatment preferences or knowledge, and usability scores were similar for both platforms.
  5. The study's limitations included a small sample size and the single-center design, affecting generalizability of the findings.
...more

MDSpire News

  • August 28, 2026
Newborn variants may flag childhood cancer predisposition
  • Andrea Surnit
  • August 28, 2026
  • 4 min

Objective: To identify pathogenic or likely pathogenic cancer-predisposition variants in newborns and estimate their association with early-onset cancers. Appro

...more
2 min

Baptist Health South Florida

  • August 28, 2026
Baptist Health Heart & Vascular Care to Host 43rd Annual Echocardiography and Structural Heart Symposium
  • August 28, 2026
  • 4 min

Objective: To explore the latest advances in cardiac imaging, valvular heart disease, and structural heart interventions. Approach: Event Details: The symposium

...more
2 min

MDSpire News

  • August 28, 2026
FDA monthly preview: Key September decisions to watch
  • Kathryn Wighton
  • August 28, 2026
  • 5 min

Objective: To outline upcoming FDA regulatory decisions for various therapies and products in September 2026. Approach: Oncology: TLX101-Px for glioma and zides

...more

The Ophthalmologist

  • August 28, 2026
Chinese Trial Validates Scleral Lenses
  • August 28, 2026
  • 3 min

Objective: To evaluate the effectiveness and safety of a four-zone scleral lens design for visual rehabilitation in Chinese patients with irregular corneas. App

...more

The Ophthalmologist

  • August 28, 2026
New Treatment for TED
  • August 28, 2026
  • 8 min
  1. In June 2026, the FDA approved Viridian Therapeutics’ Lumvoa™ for treating active and chronic thyroid eye disease (TED).
  2. Lumvoa is the first treatment to show statistically significant diplopia response and resolution in TED, according to the THRIVE clinical program.
  3. Clinical trials indicated that Lumvoa resulted in nearly 3 millimeters of proptosis reduction and significant improvement in diplopia.
  4. Approximately 70% of patients experienced a proptosis reduction of greater than two millimeters, while close to 60% showed improvement in double vision.
  5. Lumvoa demonstrated a favorable side-effect profile, with hearing symptoms reported in about 5% of patients during clinical trials.
...more

MDSpire News

  • August 28, 2026
Tirzepatide’s cardiovascular effects in clinical practice
  • Kathryn Wighton
  • August 28, 2026
  • 4 min

Objective: To compare the 1-year risk of major adverse cardiovascular events (MACE) between tirzepatide and sitagliptin in patients with type 2 diabetes and est

...more
2 min

The Pathologist

  • August 28, 2026
Petri Dishes, Powerful Lessons
  • Jessica Allerton
  • August 28, 2026
  • 5 min

Objective: To explore how creativity through #PathArt can enhance microbiology education. Approach: Creative Teaching Methods: Incorporation of agar art and mic

...more
1 min

The Pathologist

  • August 28, 2026
Blood Biomarker May Help Women Avoid Chemotherapy
  • August 28, 2026
  • 2 min

Objective: To determine if anti-Müllerian hormone (AMH) levels can identify premenopausal women with hormone receptor–positive, HER2-negative breast cancer who

...more

The Analytical Scientist

  • August 28, 2026
Continuous Monitoring Boosts Liver Assessment
  • August 28, 2026
  • 2 min

Objective: To evaluate a point-of-care monitoring platform for continuous biochemical assessment of donor livers during transplantation. Approach: Monitoring Sy

...more

Frontiers In Oncology

  • August 28, 2026
Combining Intratumoral and Peritumoral Radiomics with Deep Transfer Learning from Multiparametric MRI for Preoperative Assessment of HER2 Status in Breast Cancer: A Multicenter Investigation
  • Saisai Zhang
  • Jing Rong
  • Tiantian Liu
  • Xiujuan Yin
  • Shuqin Xue
  • Likang Yin
  • Lei Liu
  • Yang Ji
  • Xijun Gong
  • Xiao Wang
  • August 28, 2026
  1. The study assessed a model combining clinical indicators with radiomics and deep transfer learning for predicting HER2 status in breast cancer.
  2. Data from 411 breast cancer patients across three centers were used, with cohorts for training, internal validation, and external testing.
  3. The combined model achieved AUCs of 0.965 in the training cohort and 0.904 in the internal validation cohort for HER2 status prediction.
  4. External test sets demonstrated AUCs of 0.844 and 0.846, indicating the model's predictive performance across different populations.
  5. The model integrates intratumoral and peritumoral features from multiparametric MRI, enhancing the accuracy of HER2 status assessment.
...more

Frontiers In Immunology

  • August 28, 2026
Infections and Hypogammaglobulinemia Among Myasthenia Gravis Patients on Long-Term Low-Dose Rituximab: Findings from a Retrospective Cohort Analysis
  • Rongjing Guo
  • Yifan Zhang
  • Ting Gao
  • Zhe Ruan
  • Chao Sun
  • Sijia Hao
  • Yonglan Tang
  • Qingqing Wang
  • Xiaoxi Huang
  • Xiangqi Cao
  • Zhuyi Li
  • Danni Liu
  • Yu Liu
  • Ting Chang
  • August 28, 2026
  1. The study analyzed infection and hypogammaglobulinemia incidence in 186 myasthenia gravis patients on long-term low-dose rituximab.
  2. Infections occurred in 15.59% of patients, with lower respiratory tract infections being the most common.
  3. Hypogammaglobulinemia affected 27.42% of patients and was an independent predictor of infection risk.
  4. Higher baseline prednisone doses were significantly associated with an increased risk of severe lower respiratory tract infections.
  5. The median follow-up for patients was 2.41 years, with infection rates of 13.41 and 9.20 per 100 person-years at 1 and 2 years, respectively.
...more

Frontiers In Pediatrics

  • August 28, 2026
Outcomes of Very Preterm Infants (<32 Weeks’ Gestation) Surviving Without Major Morbidity: A Single-Center Retrospective Study on Prevalence, Trends, and Contributing Factors
  • Liu Yang
  • Yikun Zhang
  • Chuan Nie
  • Zhiren Chen
  • Yumei Jian
  • Di Zhong
  • Yuanhan Qin
  • August 28, 2026
  1. The study analyzed 1,172 very preterm infants admitted to the NICU from January 2021 to October 2025 at Guangdong Women and Children Hospital.
  2. Survival without major morbidity (SWMM) was achieved in 59.9% of the complete-care cohort, with survival rates remaining high and stable during the study period.
  3. Increased gestational age and birth weight were associated with higher odds of SWMM, while male sex and lower Apgar scores correlated with lower odds.
  4. The incidence of bronchopulmonary dysplasia and severe retinopathy of prematurity increased over time, despite stable survival rates.
  5. Discharges against medical advice (DAMA) occurred in 6.7% of VPIs, decreasing significantly with increasing gestational age.
...more

Bmc Medicine

  • August 28, 2026
Support for Behavioral Modification in Modern Obesity Management
  • Brunna Boaventura
  • Stuart W Flint
  • August 28, 2026
  1. GLP-1 receptor agonists enhance cardiometabolic health but require behavioral and psychosocial support for long-term effectiveness.
  2. Insufficient delivery of structured behavioral interventions in obesity management is linked to inadequate clinician training and poor referral routes.
  3. Weight stigma significantly hinders obesity care, necessitating interventions that address its psychological and social consequences.
  4. Behavior change support should encompass coping mechanisms for weight stigma, beyond just promoting health-related behaviors.
  5. Access to obesity medications may lead patients to prioritize medication over comprehensive care, perpetuating a weight-centered approach.
...more